Metastatic dissemination occurs very early in the malignant progression of a cancer but the
clinical manifestation of metastases often takes years. In recent decades, 5-year survival of …

The bone is the third most common site of metastasis for a wide range of solid tumors
including lung, breast, prostate, colorectal, thyroid, gynecologic, and melanoma, with 70% of …

The immunosuppressive microenvironment of solid tumours reduces the antitumour activity
of chimeric antigen receptor T cells (CAR-T cells). Here, we show that the release—through …

Abstract Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall
survival of a subset of patients across multiple solid tumour types, but other patients can …

Surgery is a crucial intervention and provides a chance of cure for patients with cancer. The
perioperative period is characterized by an increased risk for accelerated growth of …

Activation of the stimulator of interferon gene (STING) pathway within the tumor
microenvironment has been shown to generate a strong antitumor response. Although local …

Cancer recurrence after surgical resection remains a significant challenge in cancer therapy.
Platelets, which accumulate in wound sites and interact with circulating tumour cells (CTCs) …

The tumor microenvironment (TME) not only plays a pivotal role during cancer progression
and metastasis but also has profound effects on therapeutic efficacy. In the case of …

The hallmarks of cancer comprise six biological capabilities acquired during the multistep
development of human tumors. The hallmarks constitute an organizing principle for …

Despite great efforts and advancement in the treatment of cancer, tumor recurrence and
metastasis remain significant challenges and demand novel therapy strategies. Recently …